| Valuation method | Value, ¥ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 674.07 | -22 |
| Intrinsic value (DCF) | 567.40 | -34 |
| Graham-Dodd Method | 203.66 | -76 |
| Graham Formula | 914.20 | 6 |
FINDEX Inc. (3649.T) is a Tokyo-based healthcare technology company specializing in medical systems and software solutions for hospitals and clinics in Japan. Founded in 1985 and formerly known as PSC Inc., the company rebranded to FINDEX in 2014. Its flagship products include Claio, a medical imaging database management system, and C-Note, a progress note system designed to streamline clinical documentation. Additionally, FINDEX offers DocuMaker for document management and GAP/GAP-screener, a gaze-analyzing perimeter used in ophthalmology. The company serves a broad range of medical institutions, leveraging its expertise in healthcare IT to improve efficiency and patient care. Operating in the Medical - Healthcare Information Services sector, FINDEX plays a critical role in Japan's digital healthcare transformation, combining R&D innovation with practical clinical applications. With a market cap of approximately ¥18.7 billion, the company maintains a strong balance sheet with zero debt and solid cash reserves.
FINDEX presents a niche investment opportunity in Japan's growing healthcare IT sector, supported by stable revenue (¥5.84 billion in FY2024) and robust profitability (net income of ¥1.16 billion). The company’s debt-free balance sheet and consistent operating cash flow (¥1.9 billion) underscore financial stability. A low beta (0.394) suggests defensive characteristics, while a ¥15/share dividend reflects shareholder returns. However, reliance on the domestic market and modest market cap may limit scalability compared to global peers. Investors should weigh its strong position in Japanese hospital systems against potential competition from larger multinational medtech firms expanding into healthcare software.
FINDEX competes in Japan’s specialized healthcare IT market with a focus on hospital workflow solutions. Its competitive advantage lies in deep localization—tailoring products like Claio and C-Note to Japanese clinical practices and regulatory requirements, which global players often struggle to replicate. The company’s integrated systems (e.g., combining imaging databases with progress notes) create stickiness among hospital clients. However, its small scale (¥5.8B revenue) limits R&D budgets compared to multinational rivals. FINDEX’s zero debt and in-house development capability allow agile updates, but it lacks AI-driven analytics features increasingly offered by competitors. While defensible in mid-sized Japanese hospitals, it faces pressure from: (1) global EHR giants expanding into Asia, (2) domestic telecom/IT firms leveraging cloud infrastructure, and (3) startups targeting niche diagnostics. Its gaze-analysis perimeter (GAP) holds IP potential but operates in a limited market. Sustainability hinges on expanding beyond document management into predictive analytics and telehealth integrations.